Professor, Internal Medicine, University of Michigan Medical School
Nephrology
Dr. Alan B. Leichtman, MD
|
|
Give Review
Alan Leichtman practices Nephrology. He over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Alan Leichtman is a published MD. He published 100 publications, including: 'Prognosis after primary renal transplant failure and the beneficial effects of repeat transplantation: multivariate analyses from the United States Renal Data System.' Dr. Alan B. Leichtman accepts Medicare payments and is registered with Medicare.gov.
Publications
- The global diffusion of organ transplantation: trends, drivers and policy implications.
- Efficacy of plasmapheresis on donor-specific antibody reduction by HLA specificity in post-Kidney transplant recipients.
- Optimal Decisions for Organ Exchanges in a Kidney Paired Donation Program.
- Patient Selection and Volume in the Era Surrounding Implementation of Medicare Conditions of Participation for Transplant Programs.
- Variation in Access to the Liver Transplant Waiting List in the United States.
- Health-Related Quality of Life in Kidney Donors From the Last Five Decades: Results From the RELIVE Study.
- Dynamic challenges inhibiting optimal adoption of Kidney paired donation: findings of a consensus conference.
- Demographic, metabolic, and blood pressure characteristics of living Kidney donors spanning five decades.
- Comparison of communication and personal characteristics of living Kidney donors and a matched quota sample.
- Graph-based optimization algorithm and software on Kidney exchanges.
- Utilization of Kidneys With Similar Kidney Donor Risk Index Values From Standard Versus Expanded Criteria Donors.
- Transplanting Kidneys Without Points for HLA-B Matching: Consequences of the Policy Change.
- Improving the allocation system for deceased-donor Kidneys.
- Insurance type and minority status associated with large disparities in prelisting dialysis among candidates for Kidney transplantation.
- Kidney transplantation as primary therapy for end-stage renal disease: a National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQITM) conference.
- Balancing efficacy and toxicity in Kidney-transplant immunosuppression.
- Impact of the expanded criteria donor allocation system on candidates for and recipients of expanded criteria donor Kidneys.
- The rationale for the new deceased donor pancreas allocation schema.
- Kidney vending: the "Trojan horse" of organ transplantation.
- Impact of the expanded criteria donor allocation system on the use of expanded criteria donor Kidneys.
- Development and current status of ECD Kidney transplantation.
- Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable Renal transplant patients: a multicenter, randomized, placebo-controlled, phase I ...
- Internet-based intervention to promote organ donor registry participation and family notification.
- Longitudinal assessment of mortality risk among candidates for liver transplantation.
- Organ donors with positive viral serology or malignancy: risk of Disease transmission by transplantation.
- Evaluation of pancreatic allograft dysfunction by laparoscopic biopsy.
- Gender imbalance in living donor Renal transplantation.
- Predictability of survival models for waiting list and transplant patients: calculating LYFT.
- Kidney and pancreas transplantation in the United States, 1998-2007: access for patients with diabetes and end-stage renal disease.
- Should pediatric patients wait for HLA-DR-matched Renal transplants?
- Calculating life years from transplant (LYFT): methods for Kidney and Kidney-pancreas candidates.
- Kidney and pancreas transplantation in the United States, 1997-2006: the HRSA Breakthrough Collaboratives and the 58 DSA Challenge.
- Determinants of discard of expanded criteria donor Kidneys: impact of biopsy and machine perfusion.
- Repeat organ transplantation in the United States, 1996-2005.
- Geographic variability in access to primary Kidney transplantation in the United States, 1996-2005.
- Developing organ offer and acceptance measures: when ''good'' organs are turned down.
- Access and outcomes among minority transplant patients, 1999-2008, with a focus on determinants of Kidney graft survival.
- Immunosuppression: evolution in practice and trends, 1994-2004.
- Mortality after Kidney transplantation: a comparison between the United States and Canada.
- Report of a National Conference on Donation after cardiac death.
- Long-term survival in Renal transplant recipients with graft function.
- Renal transplantation in end-stage sickle cell nephropathy.
- A practical approach to evaluate the potential donor pool and trends in cadaveric Kidney donation.
- Prognosis after primary renal transplant Failure and the beneficial effects of repeat transplantation: multivariate analyses from the United States Renal Data System.
- Renal transplantation for systemic lupus erythematosis: excellent long-term results with both living and cadaveric donors.
- Iterative cooperative prototyping in the design of web-based transplant information systems.
- Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine.
- Long-term renal allograft survival: prognostic implication of the timing of Acute rejection episodes.
- Gadolinium-enhanced magnetic resonance angiography of Renal transplants.
- Gender discrepancies in living related Renal transplant donors and recipients.
- Pancreas transplantation for Diabetes mellitus.
- Potential Renal donors: comparison of conventional imaging with helical CT.
- Inferior outcome of two-haplotype matched Renal transplants in blacks: role of early rejection.
- Steady-state concentration of cyclosporin G (OG37-325) and its metabolites in Renal transplant recipients.
- Prediction of interpatient and intrapatient variation in OG 37-325 dosing requirements by the erythromycin breath test. A prospective study in Renal transplant recipie...
- Biotransformation of cyclosporin G in comparison to cyclosporine.
- P450 3A activity and cyclosporine dosing in Kidney and heart transplant recipients.
- Usefulness of dobutamine stress echocardiography in detecting coronary artery Disease in end-stage renal Disease.
- A prospective study of Renal structure and function in psoriasis patients treated with cyclosporin.
- Case report: reversal of left ventricular systolic dysfunction after Renal transplantation in a patient with a diabetic nephropathy.
- Relative impact of donor type on Renal allograft survival in black and white recipients.
- Evaluation of living Renal donors. The current practice of US transplant centers.
- Cholesterol emboli presenting as Acute allograft dysfunction after renal transplantation.
- Therapeutic approach to Renal transplantation: triple therapy and beyond.
- Blocking of T cell activation at the G1A/G1B interface of the cell cycle and prevention of expression of interleukin 2 receptors by alloactivated suppressor T lymphocy...
- Differential effect of gamma-irradiated and heat-treated lymphocytes on T cell activation, and interleukin-2 and interleukin-3 release in the human mixed lymphocyte re...
- Duplex imaging of the Renal transplant.
- A primary central nervous system T cell lymphoma in a Renal transplant patient.
- High-performance liquid chromatographic analysis of cyclosporin G (Nva2-cyclosporine) in human blood.
- Erythromycin breath test predicts oral clearance of cyclosporine in Kidney transplant recipients.
- Survival in recipients of marginal cadaveric donor Kidneys compared with other recipients and wait-listed transplant candidates.
- Effect of mycophenolate mofetil on long-term outcomes in African american Renal transplant recipients.
- Increased impact of Acute rejection on chronic allograft failure in recent era.
- Renal transplantation at the University of Michigan 1964 to 1999.
- Effect of waiting time on Renal transplant outcome.
- African-American Renal transplant recipients experience decreased risk of death due to infection: possible implications for immunosuppressive strategies.
- Relationship of recipient age and development of chronic allograft Failure.
- Impact of pre-existing donor hypertension and diabetes mellitus on cadaveric Renal transplant outcomes.
- Mycophenolate mofetil reduces late renal allograft loss independent of Acute rejection.
- Randomized controlled trial of hand-assisted laparoscopic versus open surgical live donor nephrectomy.
- Long-term benefit of Kidney-pancreas transplants in type 1 diabetics.
- Differences in etiology for graft loss in female Renal transplant recipients.
- Deleterious effect of waiting time on Renal transplant outcome.
- Need for individualized immunosuppression in elderly Renal transplant recipients.
- Time to first graft loss as a risk factor for second Renal allograft loss.
- Recipient age as an independent risk factor for chronic renal allograft Failure.
- Mycophenolate mofetil decreases the risk for chronic renal allograft Failure.
- Gender differences in the risk for chronic renal allograft Failure.
- Interaction of mycophenolate mofetil and HLA matching on Renal allograft survival.
- The impact of simultaneous pancreas-Kidney transplantation on long-term patient survival.
- Consensus statement on the live organ donor.
- Excellent outcome of renal transplantation in patients with Fabry's Disease.
- Increased immunosuppressive vulnerability in elderly Renal transplant recipients.
- Dialysis modality and the risk of allograft thrombosis in adult Renal transplant recipients.
- Living Kidney donor decision making and communication.
- A report of the Lisbon Conference on the care of the Kidney transplant recipient.
- Promotion of altruistic donation.
- Report of the American Society of Transplantation conference on immunosuppressive drugs and the use of generic immunosuppressants.
- Kidney and pancreas transplantation.
Schools
Michigan State University College Of Human Medicine
Providence Hospital
Beth IsraelHarvard
Procedures Preformed
- Hemodialysis
Conditions Treated
- Acidosis
- Acute Glomerulonephritis
- Acute Kidney Failure
- Calcium Metabolism Disorders
- View All
Doctors Specialties
- Nephrology
Accepted Insurances
- Choice Plus POS II
- Amerigroup (Wellpoint)
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Blue Care Network PCP Focus Network
- Group Employees PPO
- CareSource
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Cofinity PPO
- Commercial Insurance Company
- Coventry Health Care
- First Health (Coventry Health Care) PPO
- Frontpath Health Coalition
- Golden Rule
- Health Alliance
- Preferred PPO
- Choice Care PPO
- McLaren Health Plan
- Medicaid
- Medicare MCR
- Molina
- MultiPlan PPO
- PHCS Network PPO
- Mutual of Omaha
- NGS CoreSource
- PHP-Physicians Health Plan
- Priority PPO
- Choice Plus POS
- Options PPO
- United Healthcare
- Wells Fargo Insurance
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Beth Israel Deaconess Medical Center -
Providence Hospital and Medical Centers -
Michigan State University College of Human Medicine
Hospital
-
University of Michigan Hospitals and Health Centers
Drug Facts
| NPI NUMBER | 1134201049 | |
| NPPES Provider LastName | LEICHTMAN | |
| NPPES Provider FirstName | ALAN | |
| NPPES Provider ZIPCode | 481095364 | |
| NPPES Provider State | MI | |
| Specialty Description | Nephrology | |
| Total Claim Count | 1046.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1134201049 |
| Last Name Of The Provider | LEICHTMAN |
| First Name Of The Provider | ALAN |
| View All |
Similar Doctors
|
|
Dr. Chen H. Hsu, MD |
|
|
Dr. Frank C. Brosius, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William F. Weitzel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rachel L. Perlman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Silas P. Norman, MD |
|
|
Dr. Crystal A. Gadegbeku, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Harvey D. Humes, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Fu L. Luan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bruce M. Robinson, MD |